Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc (NQ: VRCA )

0.9566 +0.0692 (+7.80%)
Streaming Delayed Price Updated: 12:58 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 776,333
Open 0.8960
Bid (Size) 0.9509 (8)
Ask (Size) 0.9596 (2)
Prev. Close 0.8874
Today's Range 0.8500 - 1.024
52wk Range 0.7043 - 11.41
Shares Outstanding 41,957,197
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verrica Announces Pricing of $42.0 Million Public Offering
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Announces Proposed Public Offering
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
-85.95%
-85.95%
1 Month
-39.07%
-39.07%
3 Month
-67.13%
-67.13%
6 Month
-89.43%
-89.43%
1 Year
-74.08%
-74.08%

More News

Read More
This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500 Gains 1%; Vimeo Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
US Stocks Mixed; Inflation Rate Falls More Than Projected
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.